Premium
N‐ myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS
Author(s) -
Dias P.,
Kumar P.,
Marsden H. B.,
Gattamaneni H. R.,
Heighway J.,
Kumar S.
Publication year - 1990
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910450403
Subject(s) - gene , exact test , biology , gene duplication , microbiology and biotechnology , n myc , pathology , genetics , medicine , cell culture , neuroblastoma , ganglioneuroma
Abstract DNA from 13 (6 alveolar and 7 embryonal) childhood rhabdomyosarcomas (RMS) was examined to determine the incidence and prognostic relevance of N‐ and c‐ myc genes. Southern analysis showed 5‐ to 20‐fold amplification of N‐ myc gene in 4 of 6 alveolar but in none of 7 embryonal RMS ( p < 0.04; Fisher's exact test). The number of children who died with multiple‐ and single‐copy N‐ myc gene was 4/4 and 5/9 respectively ( p > 0.05; Chi‐squared test). There was no statistically significant correlation between N‐ myc amplification and age, gender, site, stage or survival time. There was no amplification or gross rearrangement of c‐ myc in any of the 13 RMS.